{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:40:42Z","timestamp":1785526842233,"version":"3.56.0"},"reference-count":243,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007446","name":"King Khalid University","doi-asserted-by":"publisher","award":["RGP2\/485\/45"],"award-info":[{"award-number":["RGP2\/485\/45"]}],"id":[{"id":"10.13039\/501100007446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bcp.2025.116928","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T19:03:32Z","timestamp":1745607812000},"page":"116928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Nanoformulations: Reforming treatment for non-small cell lung cancer metastasis"],"prefix":"10.1016","volume":"238","author":[{"given":"Shristy","family":"Jha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangala","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchira","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S.","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib M.","family":"Fardoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothsna","family":"Unnikrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8677-8475","authenticated-orcid":false,"given":"Gautam","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajaikumar B.","family":"Kunnumakkara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.116928_b0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3892\/mco.2014.410","article-title":"Specific organ metastases and survival in metastatic non-small-cell lung cancer","volume":"3","author":"Tamura","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b0010","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer","volume":"86","author":"Riihimaki","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2025.116928_b0015","article-title":"Non-small Cell Lung Carcinoma With Metastases to Various Levels of Vertebra: A Case Report and Literature Review","volume":"15","author":"Inban","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.bcp.2025.116928_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/biom9120836","article-title":"TIPE2 Induced the Proliferation, Survival, and Migration of Lung Cancer Cells Through Modulation of Akt\/mTOR\/NF-kappaB Signaling Cascade","volume":"9","author":"Bordoloi","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.bcp.2025.116928_b0025","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ccm.2011.08.003","article-title":"Molecular biology of lung cancer: clinical implications","volume":"32","author":"Larsen","year":"2011","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.bcp.2025.116928_b0030","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","article-title":"Recent advances in non-small cell lung cancer targeted therapy; an update review","volume":"23","author":"Araghi","year":"2023","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.bcp.2025.116928_b0035","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b0040","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","article-title":"Update 2020: Management of Non-Small Cell Lung Cancer","volume":"198","author":"Alexander","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.bcp.2025.116928_b0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/17425247.2021.1825377","article-title":"Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I","volume":"18","author":"Upadhya","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.bcp.2025.116928_b0050","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1055\/s-0033-1358552","article-title":"Personalizing therapy in advanced non-small cell lung cancer","volume":"34","author":"Villaruz","year":"2013","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.bcp.2025.116928_b0055","first-page":"36","article-title":"Targeted therapy for non-small cell lung cancer: current standards and the promise of the future","volume":"4","author":"Chan","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.bcp.2025.116928_b0060","first-page":"109","article-title":"Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy","volume":"8","author":"Santarpia","year":"2017","journal-title":"Lung Cancer (auckl)"},{"key":"10.1016\/j.bcp.2025.116928_b0065","doi-asserted-by":"crossref","unstructured":"Hoang, T.; Myung, S.K.; Pham, T.T.; Park, B. Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials. Cancers (Basel) 2020, 12, doi:10.3390\/cancers12030526.","DOI":"10.3390\/cancers12030526"},{"key":"10.1016\/j.bcp.2025.116928_b0070","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4143\/crt.2022.078","article-title":"Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer","volume":"54","author":"Rivera-Concepcion","year":"2022","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.bcp.2025.116928_b0075","doi-asserted-by":"crossref","DOI":"10.1093\/jncimonographs\/lgz008","article-title":"Potential Successes and Challenges of Targeted Cancer Therapies","volume":"2019","author":"Keefe","year":"2019","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.bcp.2025.116928_b0080","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/JCO.23.01524","article-title":"First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?","volume":"42","author":"Uprety","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b0085","doi-asserted-by":"crossref","first-page":"LMT36","DOI":"10.2217\/lmt-2020-0003","article-title":"Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver","volume":"9","author":"Kim","year":"2020","journal-title":"Lung Cancer Manag"},{"key":"10.1016\/j.bcp.2025.116928_b0090","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.semradonc.2010.01.003","article-title":"The tumor microenvironment in non-small-cell lung cancer","volume":"20","author":"Graves","year":"2010","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b0095","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1158\/0008-5472.CAN-20-3991","article-title":"Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2025.116928_b0100","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3892\/ol.2021.13048","article-title":"Immune checkpoints and immunotherapy in non-small cell lung cancer: Novel study progression, challenges and solutions","volume":"22","author":"Ma","year":"2021","journal-title":"Oncol Lett"},{"key":"10.1016\/j.bcp.2025.116928_b0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/btm2.10005","article-title":"Engineering nanoparticles to overcome barriers to immunotherapy","volume":"1","author":"Toy","year":"2016","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.bcp.2025.116928_b0110","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","article-title":"Enhancing cancer immunotherapy with nanomedicine","volume":"20","author":"Irvine","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bcp.2025.116928_b0115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","article-title":"Nanoparticles for Cancer Therapy: Current Progress and Challenges","volume":"16","author":"Gavas","year":"2021","journal-title":"Nanoscale Res Lett"},{"key":"10.1016\/j.bcp.2025.116928_b0120","doi-asserted-by":"crossref","DOI":"10.1002\/marc.201800917","article-title":"pH-Responsive Polymer Nanoparticles for Drug Delivery","volume":"40","author":"Deirram","year":"2019","journal-title":"Macromol Rapid Commun"},{"key":"10.1016\/j.bcp.2025.116928_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/ma12182889","article-title":"Combining Carbon Nanotubes and Chitosan for the Vectorization of Methotrexate to Lung Cancer Cells","volume":"12","author":"Cirillo","year":"2019","journal-title":"Materials (basel)"},{"key":"10.1016\/j.bcp.2025.116928_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1154318","article-title":"The use of nanoparticles for targeted drug delivery in non-small cell lung cancer","volume":"13","author":"Holder","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b0135","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.2147\/DDDT.S151422","article-title":"Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo","volume":"11","author":"Tan","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bcp.2025.116928_b0140","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3109\/1061186X.2011.622404","article-title":"Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA","volume":"19","author":"Taratula","year":"2011","journal-title":"J Drug Target"},{"key":"10.1016\/j.bcp.2025.116928_b0145","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.taap.2014.01.012","article-title":"Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy","volume":"275","author":"Sundarraj","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.bcp.2025.116928_b0150","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2174\/1389557516666161013111155","article-title":"LHRH-Targeted Drug Delivery Systems for Cancer Therapy","volume":"17","author":"Li","year":"2017","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.bcp.2025.116928_b0155","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fmolb.2020.00193","article-title":"Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance","volume":"7","author":"Yao","year":"2020","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.bcp.2025.116928_b0160","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s11671-019-3143-3","article-title":"Cancer Cell Membrane Decorated Silica Nanoparticle Loaded with miR495 and Doxorubicin to Overcome Drug Resistance for Effective Lung Cancer Therapy","volume":"14","author":"He","year":"2019","journal-title":"Nanoscale Res Lett"},{"key":"10.1016\/j.bcp.2025.116928_b0165","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","article-title":"The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting","volume":"41","author":"Maeda","year":"2001","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.bcp.2025.116928_b0170","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2025.116928_b0175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jconrel.2016.07.028","article-title":"Accumulating nanoparticles by EPR: A route of no return","volume":"238","author":"Ngoune","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.bcp.2025.116928_b0180","doi-asserted-by":"crossref","first-page":"280","DOI":"10.37349\/emed.2024.00221","article-title":"Physiologically driven nanodrug delivery system for targeted lung cancer treatment","volume":"5","author":"Zhang","year":"2024","journal-title":"Exploration of Medicine"},{"key":"10.1016\/j.bcp.2025.116928_b0185","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1517\/17425240902932908","article-title":"Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy","volume":"6","author":"Gindy","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.bcp.2025.116928_b0190","doi-asserted-by":"crossref","DOI":"10.1142\/S179398442450003X","article-title":"Ellagic Acid-Gold Nanoparticle Complex as Anticancer Agent in Triple-Negative Breast Cancer Cells","volume":"14","author":"Unnikrishnan","year":"2024","journal-title":"Nano LIFE"},{"key":"10.1016\/j.bcp.2025.116928_b0195","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.7150\/thno.17098","article-title":"Size Dependent Kinetics of Gold Nanorods in EPR Mediated Tumor Delivery","volume":"6","author":"Tong","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2025.116928_b0200","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/annonc\/mdl104","article-title":"Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer","volume":"17","author":"Green","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b0205","article-title":"Application of Nanoparticles in the Treatment of Lung Cancer With Emphasis on Receptors","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bcp.2025.116928_b0210","doi-asserted-by":"crossref","first-page":"140","DOI":"10.18053\/jctres.07.202102.005","article-title":"Current role of nanoparticles in the treatment of lung cancer","volume":"7","author":"Carrasco-Esteban","year":"2021","journal-title":"J Clin Transl Res"},{"key":"10.1016\/j.bcp.2025.116928_b0215","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.tips.2019.04.002","article-title":"Adding Nanotechnology to the Metastasis Treatment Arsenal","volume":"40","author":"Banerjee","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bcp.2025.116928_b0220","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.3390\/ijms23084153","article-title":"Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology","volume":"23","author":"Hersh","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bcp.2025.116928_b0225","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/JOP.19.00357","article-title":"Management of Brain Metastases in Non-Small-Cell Lung Cancer","volume":"15","author":"Ernani","year":"2019","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.bcp.2025.116928_b0230","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nmat4822","article-title":"Designer vaccine nanodiscs for personalized cancer immunotherapy","volume":"16","author":"Kuai","year":"2017","journal-title":"Nat Mater"},{"key":"10.1016\/j.bcp.2025.116928_b0235","doi-asserted-by":"crossref","first-page":"7051","DOI":"10.1039\/D0NR00080A","article-title":"Dual photothermal MDSCs-targeted immunotherapy inhibits lung immunosuppressive metastasis by enhancing T-cell recruitment","volume":"12","author":"Domvri","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.bcp.2025.116928_b0240","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41420-024-02121-0","article-title":"Nanomedicine-induced programmed cell death in cancer therapy: mechanisms and perspectives","volume":"10","author":"Luobin","year":"2024","journal-title":"Cell Death Discovery"},{"key":"10.1016\/j.bcp.2025.116928_b0245","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3390\/pharmaceutics14071326","article-title":"PLGA-Quercetin Nano-Formulation Inhibits Cancer Progression via Mitochondrial Dependent Caspase-3,7 and Independent FoxO1 Activation with Concomitant PI3K\/AKT Suppression","volume":"14","author":"Yadav","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2025.116928_b0250","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.3390\/molecules27206862","article-title":"Rubus Capped Zinc Oxide Nanoparticles Induce Apoptosis in MCF-7 Breast Cancer Cells","volume":"27","author":"George","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2025.116928_b0255","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.nano.2018.09.002","article-title":"Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms","volume":"15","author":"Zhang","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.bcp.2025.116928_b0260","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1039\/C9BM01563A","article-title":"Polyethyleneimine coated Fe(3)O(4) magnetic nanoparticles induce autophagy, NF-kappaB and TGF-beta signaling pathway activation in HeLa cervical carcinoma cells via reactive oxygen species generation","volume":"8","author":"Man","year":"2020","journal-title":"Biomater Sci"},{"key":"10.1016\/j.bcp.2025.116928_b0265","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jconrel.2023.01.028","article-title":"Graphene oxide nanoarchitectures in cancer biology: Nano-modulators of autophagy and apoptosis","volume":"354","author":"Taheriazam","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.bcp.2025.116928_b0270","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10430","article-title":"An iRGD-conjugated photothermal therapy-responsive gold nanoparticle system carrying siCDK7 induces necroptosis and immunotherapeutic responses in lung adenocarcinoma","volume":"8","author":"Cai","year":"2023","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.bcp.2025.116928_b0275","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","article-title":"Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy","volume":"7","author":"Gao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bcp.2025.116928_b0280","doi-asserted-by":"crossref","first-page":"eaba9772","DOI":"10.1126\/scitranslmed.aba9772","article-title":"Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models","volume":"13","author":"Lin","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bcp.2025.116928_b0285","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1083\/jcb.201211138","article-title":"Extracellular vesicles: exosomes, microvesicles, and friends","volume":"200","author":"Raposo","year":"2013","journal-title":"J Cell Biol"},{"key":"10.1016\/j.bcp.2025.116928_b0290","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-cellbio-101512-122326","article-title":"Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles","volume":"30","author":"Colombo","year":"2014","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.bcp.2025.116928_b0295","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cytogfr.2023.06.001","article-title":"Exosomal noncoding RNA-mediated spatiotemporal regulation of lipid metabolism: Implications in immune evasion and chronic inflammation","volume":"73","author":"Hegde","year":"2023","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.bcp.2025.116928_b0300","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12967-021-02985-1","article-title":"The role of exosomes in lung cancer metastasis and clinical applications: an updated review","volume":"19","author":"Yin","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.bcp.2025.116928_b0305","doi-asserted-by":"crossref","unstructured":"Sandua, A.; Alegre, E.; Gonzalez, A. Exosomes in Lung Cancer: Actors and Heralds of Tumor Development. Cancers (Basel) 2021, 13, doi:10.3390\/cancers13174330.","DOI":"10.3390\/cancers13174330"},{"key":"10.1016\/j.bcp.2025.116928_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1142539","article-title":"Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer","volume":"14","author":"Rao","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.bcp.2025.116928_b0315","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1369356","article-title":"Extracellular vesicles in non-small cell lung cancer stemness and clinical applications","volume":"15","author":"Pandya","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.bcp.2025.116928_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106516","article-title":"The role of extracellular vesicles in non-small-cell lung cancer, the unknowns, and how new approach methodologies can support new knowledge generation in the field","volume":"188","author":"Mullen","year":"2023","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.bcp.2025.116928_b0325","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/biomedicines12010123","article-title":"Extracellular Vesicles and Exosomes: Novel Insights and Perspectives on Lung Cancer from Early Detection to Targeted Treatment","volume":"12","author":"Rahimian","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2025.116928_b0330","doi-asserted-by":"crossref","unstructured":"Salunkhe, S.; Dheeraj; Basak, M.; Chitkara, D.; Mittal, A. Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: Strategies and significance. J Control Release 2020, 326, 599-614, doi:10.1016\/j.jconrel.2020.07.042.","DOI":"10.1016\/j.jconrel.2020.07.042"},{"key":"10.1016\/j.bcp.2025.116928_b0335","doi-asserted-by":"crossref","unstructured":"Ashrafi, A.; Akter, Z.; Modareszadeh, P.; Modareszadeh, P.; Berisha, E.; Alemi, P.S.; Chacon Castro, M.D.C.; Deese, A.R.; Zhang, L. Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. Cancers (Basel) 2022, 14, doi:10.3390\/cancers14194562.","DOI":"10.3390\/cancers14194562"},{"key":"10.1016\/j.bcp.2025.116928_b0340","doi-asserted-by":"crossref","first-page":"1129465","DOI":"10.3389\/fimmu.2023.1129465","article-title":"Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.bcp.2025.116928_b0345","article-title":"Rational Design of Nanoparticles with Deep Tumor Penetration for Effective Treatment of Tumor Metastasis","volume":"28","author":"Zhang","year":"2018","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.bcp.2025.116928_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216066","article-title":"Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives","volume":"556","author":"Hegde","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bcp.2025.116928_b0355","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/smll.201301992","article-title":"Cationic Bovine Serum Albumin Based Self-Assembled Nanoparticles as siRNA Delivery Vector for Treating Lung Metastatic Cancer","volume":"10","author":"Han","year":"2014","journal-title":"Small"},{"key":"10.1016\/j.bcp.2025.116928_b0360","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/cgt.2009.45","article-title":"Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis","volume":"17","author":"Rodrigo-Garzon","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.bcp.2025.116928_b0365","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2174\/1871520616666160817143656","article-title":"Docetaxel-loaded Bovine Serum Albumin Nanoparticles Conjugated Docosahexaenoic Acid for Inhibiting Lung Cancer Metastasis to Bone","volume":"17","author":"Zu","year":"2017","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.bcp.2025.116928_b0370","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10555-010-9216-5","article-title":"Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy","volume":"29","author":"Sullivan","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.bcp.2025.116928_b0375","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1021\/mp500568z","article-title":"Active targeting docetaxel-PLA nanoparticles eradicate circulating lung cancer stem-like cells and inhibit liver metastasis","volume":"12","author":"Yang","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bcp.2025.116928_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111450","article-title":"The metastasizing mechanisms of lung cancer: Recent advances and therapeutic challenges","volume":"138","author":"Xie","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bcp.2025.116928_b0385","doi-asserted-by":"crossref","first-page":"106372","DOI":"10.1016\/j.ejps.2023.106372","article-title":"Ultrasound-mediated mesoporous silica nanoparticles loaded with PDLIM5 siRNA inhibit gefitinib resistance in NSCLC cells by attenuating EMT","volume":"182","author":"Wu","year":"2023","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.bcp.2025.116928_b0390","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.2147\/IJN.S141787","article-title":"Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer","volume":"12","author":"Song","year":"2017","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.bcp.2025.116928_b0395","first-page":"8231267","article-title":"Blockage of TGF-alpha Induced by Spherical Silica Nanoparticles Inhibits Epithelial-Mesenchymal Transition and Proliferation of Human Lung Epithelial Cells","volume":"2019","author":"Li","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.bcp.2025.116928_b0400","first-page":"67","article-title":"Tackling exosome and nuclear receptor interaction: an emerging paradigm in the treatment of chronic diseases","volume":"11","author":"Aswani","year":"2024","journal-title":"Mil Med Res"},{"key":"10.1016\/j.bcp.2025.116928_b0405","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3892\/mmr.2013.1759","article-title":"More efficient induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells","volume":"9","author":"Wang","year":"2014","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.bcp.2025.116928_b0410","doi-asserted-by":"crossref","first-page":"31093","DOI":"10.1038\/srep31093","article-title":"Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.bcp.2025.116928_b0415","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1039\/C9NR09011H","article-title":"Use of lung-specific exosomes for miRNA-126 delivery in non-small cell lung cancer","volume":"12","author":"Nie","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.bcp.2025.116928_b0420","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/sci-2022-030","article-title":"Exosome-based cancer vaccine for prevention of lung cancer","volume":"10","author":"Meng","year":"2023","journal-title":"Stem Cell Investig"},{"key":"10.1016\/j.bcp.2025.116928_b0425","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbrc.2017.06.055","article-title":"Serum long non coding RNA MALAT-1 protected by exosomes is up-regulated and promotes cell proliferation and migration in non-small cell lung cancer","volume":"490","author":"Zhang","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bcp.2025.116928_b0430","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/OTT.S155134","article-title":"Exosome-mediated delivery of MALAT1 induces cell proliferation in breast cancer","volume":"11","author":"Zhang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bcp.2025.116928_b0435","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4161\/rna.20481","article-title":"The hallmarks of cancer: a long non-coding RNA point of view","volume":"9","author":"Gutschner","year":"2012","journal-title":"RNA Biol"},{"key":"10.1016\/j.bcp.2025.116928_b0440","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1097\/JTO.0b013e3182307eac","article-title":"The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth","volume":"6","author":"Schmidt","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b0445","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11095-022-03224-y","article-title":"Exosomes as Carriers for Drug Delivery in Cancer Therapy","volume":"40","author":"Zeng","year":"2023","journal-title":"Pharm Res"},{"key":"10.1016\/j.bcp.2025.116928_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109265","article-title":"Exosome-based vaccines and their position in next generation vaccines","volume":"113","author":"Negahdaripour","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.bcp.2025.116928_b0455","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3389\/fphar.2018.01116","article-title":"A New Approach for Loading Anticancer Drugs Into Mesenchymal Stem Cell-Derived Exosome Mimetics for Cancer Therapy","volume":"9","author":"Kalimuthu","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bcp.2025.116928_b0460","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1021\/acsnano.8b02053","article-title":"Modification of Extracellular Vesicles by Fusion with Liposomes for the Design of Personalized Biogenic Drug Delivery Systems","volume":"12","author":"Piffoux","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.bcp.2025.116928_b0465","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.3390\/ijms25073645","article-title":"Enhanced Therapeutic Potential of Hybrid Exosomes Loaded with Paclitaxel for Cancer Therapy","volume":"25","author":"Wang","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bcp.2025.116928_b0470","doi-asserted-by":"crossref","first-page":"16770","DOI":"10.1021\/acsnano.3c03456","article-title":"Sequential Targeting Hybrid Nanovesicles Composed of Chimeric Antigen Receptor T-Cell-Derived Exosomes and Liposomes for Enhanced Cancer Immunochemotherapy","volume":"17","author":"Zhu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.bcp.2025.116928_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115891","article-title":"Advances and challenges in the treatment of lung cancer","volume":"169","author":"Li","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bcp.2025.116928_b0480","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1345\/aph.1L200","article-title":"Therapeutic strategy for treatment of metastatic non-small cell lung cancer","volume":"42","author":"Berhoune","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.bcp.2025.116928_b0485","doi-asserted-by":"crossref","unstructured":"de Jong, D.; Das, J.P.; Ma, H.; Pailey Valiplackal, J.; Prendergast, C.; Roa, T.; Braumuller, B.; Deng, A.; Dercle, L.; Yeh, R.; et al. Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer. Cancers (Basel) 2023, 15, doi:10.3390\/cancers15102855.","DOI":"10.3390\/cancers15102855"},{"key":"10.1016\/j.bcp.2025.116928_b0490","doi-asserted-by":"crossref","unstructured":"Monisha, J.; Roy, N.K.; Padmavathi, G.; Banik, K.; Bordoloi, D.; Khwairakpam, A.D.; Arfuso, F.; Chinnathambi, A.; Alahmadi, T.A.; Alharbi, S.A.; et al. NGAL is Downregulated in Oral Squamous Cell Carcinoma and Leads to Increased Survival, Proliferation, Migration and Chemoresistance. Cancers (Basel) 2018, 10, doi:10.3390\/cancers10070228.","DOI":"10.20944\/preprints201805.0076.v1"},{"key":"10.1016\/j.bcp.2025.116928_b0495","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/1061186X.2022.2032093","article-title":"Black phosphorus nanoparticles for dual therapy of non-small cell lung cancer","volume":"30","author":"Lin","year":"2022","journal-title":"J Drug Target"},{"key":"10.1016\/j.bcp.2025.116928_b0500","doi-asserted-by":"crossref","first-page":"1600229","DOI":"10.1002\/advs.201600229","article-title":"Anti-Metastatic and Anti-Angiogenic Activities of Core-Shell SiO(2)@LDH Loaded with Etoposide in Non-Small Cell Lung Cancer","volume":"3","author":"Zhu","year":"2016","journal-title":"Adv Sci (weinh)"},{"key":"10.1016\/j.bcp.2025.116928_b0505","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/pharmaceutics14040829","article-title":"Synthesis of Novel Conjugated Linoleic Acid (CLA)-Coated Superparamagnetic Iron Oxide Nanoparticles (SPIONs) for the Delivery of Paclitaxel with Enhanced In Vitro Anti-Proliferative Activity on A549 Lung Cancer Cells","volume":"14","author":"Ngema","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2025.116928_b0510","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1021\/acsabm.3c00224","article-title":"Surface Immobilization of Anti-VEGF Peptide on SPIONs for Antiangiogenic and Targeted Delivery of Paclitaxel in Non-Small-Cell Lung Carcinoma","volume":"6","author":"Ngema","year":"2023","journal-title":"ACS Appl Bio Mater"},{"key":"10.1016\/j.bcp.2025.116928_b0515","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12032-022-01893-8","article-title":"Crizotinib loaded polydopamine-polylactide-TPGS nanoparticles in targeted therapy for non-small cell lung cancer","volume":"40","author":"Wang","year":"2022","journal-title":"Med Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b0520","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.2147\/IJN.S194304","article-title":"Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer","volume":"14","author":"Wang","year":"2019","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.bcp.2025.116928_b0525","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s13346-023-01355-2","article-title":"Medium-chain triglyceride-stabilized docetaxel-loaded HSA nanoparticles effectively inhibited metastatic non-small cell lung cancer","volume":"13","author":"Cheng","year":"2023","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.bcp.2025.116928_b0530","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12951-014-0037-5","article-title":"Anticancer drug-loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in lung cancer metastasis","volume":"12","author":"Long","year":"2014","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.bcp.2025.116928_b0535","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12943-022-01681-y","article-title":"Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC","volume":"21","author":"Sun","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bcp.2025.116928_b0540","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11095-020-02790-3","article-title":"Sorafenib Loaded Inhalable Polymeric Nanocarriers against Non-Small Cell Lung Cancer","volume":"37","author":"Shukla","year":"2020","journal-title":"Pharm Res"},{"key":"10.1016\/j.bcp.2025.116928_b0545","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.2147\/IJN.S258699","article-title":"Enhanced Anti-Brain Metastasis from Non-Small Cell Lung Cancer of Osimertinib and Doxorubicin Co-Delivery Targeted Nanocarrier","volume":"15","author":"Wang","year":"2020","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.bcp.2025.116928_b0550","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1182\/blood-2007-01-067256","article-title":"Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-kappaB activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis","volume":"109","author":"Kunnumakkara","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2025.116928_b0555","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5493\/wjem.v2.i3.45","article-title":"Natural compounds as anticancer agents: Experimental evidence","volume":"2","author":"Wang","year":"2012","journal-title":"World J Exp Med"},{"key":"10.1016\/j.bcp.2025.116928_b0560","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.phymed.2015.08.015","article-title":"Potential of butein, a tetrahydroxychalcone to obliterate cancer","volume":"22","author":"Padmavathi","year":"2015","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bcp.2025.116928_b0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118814","article-title":"Rationalizing the therapeutic potential of apigenin against cancer","volume":"267","author":"Ahmed","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.bcp.2025.116928_b0570","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/ptr.7386","article-title":"Wogonin and its analogs for the prevention and treatment of cancer: A systematic review","volume":"36","author":"Banik","year":"2022","journal-title":"Phytother Res"},{"key":"10.1016\/j.bcp.2025.116928_b0575","doi-asserted-by":"crossref","first-page":"10713","DOI":"10.1021\/acsomega.2c07326","article-title":"Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?","volume":"8","author":"Hegde","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bcp.2025.116928_b0580","first-page":"581","article-title":"Free radical scavenging, antitumor and anticarcinogenic activity of gossypin","volume":"22","author":"Babu","year":"2003","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.bcp.2025.116928_b0585","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41419-019-1789-5","article-title":"The natural compound neobractatin inhibits tumor metastasis by upregulating the RNA-binding-protein MBNL2","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2025.116928_b0590","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/iub.2522","article-title":"Xanthohumol from Hop: Hope for cancer prevention and treatment","volume":"73","author":"Girisa","year":"2021","journal-title":"IUBMB Life"},{"key":"10.1016\/j.bcp.2025.116928_b0595","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/pros.20899","article-title":"Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells","volume":"69","author":"Muralimanoharan","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.bcp.2025.116928_b0600","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.phytochem.2006.06.020","article-title":"Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives","volume":"67","author":"Nagle","year":"2006","journal-title":"Phytochemistry"},{"key":"10.1016\/j.bcp.2025.116928_b0605","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jnutbio.2005.01.017","article-title":"Resveratrol as an anticancer nutrient: molecular basis, open questions and promises","volume":"16","author":"Signorelli","year":"2005","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.bcp.2025.116928_b0610","doi-asserted-by":"crossref","first-page":"8367","DOI":"10.3390\/molecules27238367","article-title":"Natural Products as Anticancer Agents: Current Status and Future Perspectives","volume":"27","author":"Naeem","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2025.116928_b0615","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.semcancer.2019.08.014","article-title":"Natural product-based nanoformulations for cancer therapy: Opportunities and challenges","volume":"69","author":"Kashyap","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.bcp.2025.116928_b0620","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2147\/DDDT.S447496","article-title":"Advances in Nanotechnology for Enhancing the Solubility and Bioavailability of Poorly Soluble Drugs","volume":"18","author":"Liu","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bcp.2025.116928_b0625","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7010","article-title":"Integrating natural compounds and nanoparticle-based drug delivery systems: A novel strategy for enhanced efficacy and selectivity in cancer therapy","volume":"13","author":"Manzari-Tavakoli","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.bcp.2025.116928_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.fbio.2023.103095","article-title":"Nanoformulations of curcumin: An alliance for effective cancer therapeutics","volume":"56","author":"Hegde","year":"2023","journal-title":"Food Biosci."},{"key":"10.1016\/j.bcp.2025.116928_b0635","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00210-023-02603-5","article-title":"Zerumbone-incorporated liquid crystalline nanoparticles inhibit proliferation and migration of non-small-cell lung cancer in vitro","volume":"397","author":"Manandhar","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bcp.2025.116928_b0640","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.apsb.2016.01.004","article-title":"Comparison of drug release from liquid crystalline monoolein dispersions and solid lipid nanoparticles using a flow cytometric technique","volume":"6","author":"Dawoud","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bcp.2025.116928_b0645","doi-asserted-by":"crossref","first-page":"46830","DOI":"10.1007\/s11356-022-19158-2","article-title":"Berberine-loaded liquid crystalline nanoparticles inhibit non-small cell lung cancer proliferation and migration in vitro","volume":"29","author":"Paudel","year":"2022","journal-title":"Environ Sci Pollut Res Int"},{"key":"10.1016\/j.bcp.2025.116928_b0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119436","article-title":"Rutin loaded liquid crystalline nanoparticles inhibit non-small cell lung cancer proliferation and migration in vitro","volume":"276","author":"Paudel","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.bcp.2025.116928_b0655","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.tiv.2018.06.015","article-title":"Gallic acid-coated sliver nanoparticle alters the expression of radiation-induced epithelial-mesenchymal transition in non-small lung cancer cells","volume":"52","author":"Sunil Gowda","year":"2018","journal-title":"Toxicol in Vitro"},{"key":"10.1016\/j.bcp.2025.116928_b0660","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3390\/pharmaceutics14061119","article-title":"Evaluation of the Cytotoxic Activity and Anti-Migratory Effect of Berberine-Phytantriol Liquid Crystalline Nanoparticle Formulation on Non-Small-Cell Lung Cancer In Vitro","volume":"14","author":"Alnuqaydan","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2025.116928_b0665","doi-asserted-by":"crossref","first-page":"18497","DOI":"10.1038\/s41598-022-21665-8","article-title":"Novel Venetin-1 nanoparticle from earthworm coelomic fluid as a promising agent for the treatment of non-small cell lung cancer","volume":"12","author":"Rybicka","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.bcp.2025.116928_b0670","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s11626-016-0057-6","article-title":"Silver nanoparticles from Dendropanax morbifera Leveille inhibit cell migration, induce apoptosis, and increase generation of reactive oxygen species in A549 lung cancer cells","volume":"52","author":"Castro Aceituno","year":"2016","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"10.1016\/j.bcp.2025.116928_b0675","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000279388","article-title":"EGFR signaling and drug discovery","volume":"77","author":"Lurje","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.bcp.2025.116928_b0680","first-page":"1","article-title":"Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage","volume":"63","author":"Kari","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2025.116928_b0685","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2025.116928_b0690","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1021\/acs.molpharmaceut.3c00310","article-title":"Enhanced Antitumor Efficacy of Novel Biomimetic Platelet Membrane-Coated Tetrandrine Nanoparticles in Nonsmall Cell Lung Cancer","volume":"20","author":"Jiang","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bcp.2025.116928_b0695","doi-asserted-by":"crossref","unstructured":"Wu, T.; Yan, D.; Hou, W.; Jiang, H.; Wu, M.; Wang, Y.; Chen, G.; Tang, C.; Wang, Y.; Xu, H. Biomimetic Red Blood Cell Membrane-Mediated Nanodrugs Loading Ursolic Acid for Targeting NSCLC Therapy. Cancers (Basel) 2022, 14, doi:10.3390\/cancers14184520.","DOI":"10.3390\/cancers14184520"},{"key":"10.1016\/j.bcp.2025.116928_b0700","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.939158","article-title":"Manganese-Based Prussian Blue Nanocatalysts Suppress Non-Small Cell Lung Cancer Growth and Metastasis via Photothermal and Chemodynamic Therapy","volume":"10","author":"Fang","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.bcp.2025.116928_b0705","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.2147\/IJN.S362244","article-title":"Cucumber-Derived Nanovesicles Containing Cucurbitacin B for Non-Small Cell Lung Cancer Therapy","volume":"17","author":"Chen","year":"2022","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.bcp.2025.116928_b0710","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","article-title":"Smart nanoparticles for cancer therapy","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2025.116928_b0715","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.1021\/acs.jmedchem.2c00698","article-title":"Developing a Copper(II) Agent Based on His-146 and His-242 Residues of Human Serum Albumin Nanoparticles: Integration To Overcome Cisplatin Resistance and Inhibit the Metastasis of Nonsmall Cell Lung Cancer","volume":"65","author":"Jiang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2025.116928_b0720","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/open.202100070","article-title":"Distinguishable Targeting of Non-Small Cell Lung Cancer Using Hyaluronan Functionalized Platinum Nanoclusters and Their Inhibition Behaviors of Proliferation, Invasion","volume":"10","author":"Liu","year":"2021","journal-title":"Migration. Chemistryopen"},{"key":"10.1016\/j.bcp.2025.116928_b0725","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.789934","article-title":"PPy@Fe(3)O(4) Nanoparticles Inhibit Tumor Growth and Metastasis Through Chemodynamic and Photothermal Therapy in Non-small Cell Lung Cancer","volume":"9","author":"Fang","year":"2021","journal-title":"Front Chem"},{"key":"10.1016\/j.bcp.2025.116928_b0730","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1038\/s41467-024-47080-3","article-title":"Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer","volume":"15","author":"Bi","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.bcp.2025.116928_b0735","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/cells12030356","article-title":"The Role of Exosomes in Human Carcinogenesis and Cancer Therapy-Recent Findings from Molecular and Clinical Research","volume":"12","author":"Stefanska","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2025.116928_b0740","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12951-024-02414-7","article-title":"Anti-EGFR ScFv functionalized exosomes delivering LPCAT1 specific siRNAs for inhibition of lung cancer brain metastases","volume":"22","author":"Jiang","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.bcp.2025.116928_b0745","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.21037\/tcr-20-2815","article-title":"Exosomal microRNAs in non-small cell lung cancer","volume":"10","author":"Durendez-Saez","year":"2021","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.bcp.2025.116928_b0750","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13287-020-1580-7","article-title":"Exosomal microRNA-144 from bone marrow-derived mesenchymal stem cells inhibits the progression of non-small cell lung cancer by targeting CCNE1 and CCNE2","volume":"11","author":"Liang","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.bcp.2025.116928_b0755","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1111\/jcmm.17933","article-title":"Inhibitory role of bone marrow mesenchymal stem cells-derived exosome in non-small-cell lung cancer: microRNA-30b-5p, EZH2 and PI3K\/AKT pathway","volume":"27","author":"Wu","year":"2023","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.bcp.2025.116928_b0760","first-page":"1832","article-title":"BMSCs-Derived Exosomal MiR-126-3p Inhibits the Viability of NSCLC Cells by Targeting PTPN9","volume":"26","author":"Chen","year":"2021","journal-title":"J BUON"},{"key":"10.1016\/j.bcp.2025.116928_b0765","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1186\/s12935-021-02157-7","article-title":"Engineered exosomes loaded with miR-449a selectively inhibit the growth of homologous non-small cell lung cancer","volume":"21","author":"Zhou","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.bcp.2025.116928_b0770","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/s41419-021-04314-2","article-title":"Exosomal miR-338-3p suppresses non-small-cell lung cancer cells metastasis by inhibiting CHL1 through the MAPK signaling pathway","volume":"12","author":"Tian","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bcp.2025.116928_b0775","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1177\/09603271211041997","article-title":"Exosome-derived miR-2682-5p suppresses cell viability and migration by HDAC1-silence-mediated upregulation of ADH1A in non-small cell lung cancer","volume":"40","author":"Mao","year":"2021","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.bcp.2025.116928_b0780","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/1759-7714.13759","article-title":"Exosomal miR-3180-3p inhibits proliferation and metastasis of non-small cell lung cancer by downregulating FOXP4","volume":"12","author":"Chen","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.bcp.2025.116928_b0785","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4149\/neo_2021_201208N1328","article-title":"microRNA-204 shuttled by mesenchymal stem cell-derived exosomes inhibits the migration and invasion of non-small-cell lung cancer cells via the KLF7\/AKT\/HIF-1alpha axis","volume":"68","author":"Liu","year":"2021","journal-title":"Neoplasma"},{"key":"10.1016\/j.bcp.2025.116928_b0790","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12967-024-05215-6","article-title":"Exosome-transported circ_0061407 and circ_0008103 play a tumour-repressive role and show diagnostic value in non-small-cell lung cancer","volume":"22","author":"Chen","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.bcp.2025.116928_b0795","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1186\/s12935-020-01653-6","article-title":"Exosomal miR-126 blocks the development of non-small cell lung cancer through the inhibition of ITGA6","volume":"20","author":"Li","year":"2020","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.bcp.2025.116928_b0800","article-title":"Tumor Cell-Derived Exosomal miR-770 Inhibits M2 Macrophage Polarization via Targeting MAP3K1 to Inhibit the Invasion of Non-small Cell Lung Cancer Cells","volume":"9","author":"Liu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.bcp.2025.116928_b0805","doi-asserted-by":"crossref","first-page":"RP89613","DOI":"10.7554\/eLife.89613.3","article-title":"Mechanically stimulated osteocytes maintain tumor dormancy in bone metastasis of non-small cell lung cancer by releasing small extracellular vesicles","volume":"12","author":"Xie","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.bcp.2025.116928_b0810","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41420-022-01283-z","article-title":"Mesenchymal stem cell-derived extracellular vesicles transfer miR-598 to inhibit the growth and metastasis of non-small-cell lung cancer by targeting THBS2","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.bcp.2025.116928_b0815","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.yexmp.2016.05.013","article-title":"Exosomal formulation enhances therapeutic response of celastrol against lung cancer","volume":"101","author":"Aqil","year":"2016","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.bcp.2025.116928_b0820","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1080\/10717544.2021.1951894","article-title":"Docetaxel-loaded exosomes for targeting non-small cell lung cancer: preparation and evaluation in vitro and in vivo","volume":"28","author":"Wang","year":"2021","journal-title":"Drug Deliv"},{"key":"10.1016\/j.bcp.2025.116928_b0825","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/107815529600200402","article-title":"Doxil\u00ae Liposomal doxorubicin","volume":"2","author":"Patel","year":"1996","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.bcp.2025.116928_b0830","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil(R)\u2013the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.bcp.2025.116928_b0835","doi-asserted-by":"crossref","first-page":"112","DOI":"10.55730\/1300-0152.2687","article-title":"Nonsmall-cell lung cancer treatment: current status of drug repurposing and nanoparticle-based drug delivery systems","volume":"48","author":"Inci","year":"2024","journal-title":"Turk J Biol"},{"key":"10.1016\/j.bcp.2025.116928_b0840","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.2147\/OTT.S105587","article-title":"Onivyde for the therapy of multiple solid tumors","volume":"9","author":"Zhang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bcp.2025.116928_b0845","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","article-title":"FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia","volume":"25","author":"Krauss","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2025.116928_b0850","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/cas.15377","article-title":"Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs","volume":"113","author":"Milano","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bcp.2025.116928_b0855","first-page":"277","article-title":"Liposomal daunorubicin as treatment for Kaposi's sarcoma","volume":"2","author":"Petre","year":"2007","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.bcp.2025.116928_b0860","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminoncol.2004.08.001","article-title":"Advantages of liposomal delivery systems for anthracyclines","volume":"31","author":"Allen","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b0865","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1634\/theoncologist.12-8-991","article-title":"FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)","volume":"12","author":"Dinndorf","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.bcp.2025.116928_b0870","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2014.05.036","article-title":"State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines","volume":"187","author":"Dawidczyk","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.bcp.2025.116928_b0875","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2017.09.026","article-title":"Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy","volume":"267","author":"Wang","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.bcp.2025.116928_b0880","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1200\/JCO.2007.10.8605","article-title":"Phase I\/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer","volume":"26","author":"Rizvi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b0885","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1111\/1759-7714.14149","article-title":"Phase I\/II study of biweekly nab-paclitaxel in patients with platinum-pretreated non-small cell lung cancer: NJLCG1402","volume":"12","author":"Miyauchi","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.bcp.2025.116928_b0890","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/COC.0000000000000876","article-title":"Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer","volume":"44","author":"Yoshimura","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b0895","doi-asserted-by":"crossref","first-page":"13041","DOI":"10.1002\/cam4.5978","article-title":"Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial","volume":"12","author":"Sonoda","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.bcp.2025.116928_b0900","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.lungcan.2019.08.009","article-title":"A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer","volume":"136","author":"Villaruz","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2025.116928_b0905","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b0910","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/JTO.0b013e3181c0a2f4","article-title":"Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer","volume":"4","author":"Reynolds","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b0915","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jjco\/hyae044","article-title":"A single arm Phase I\/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424\/OLCSG1402: CARNAVAL)","volume":"54","author":"Nogami","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b0920","doi-asserted-by":"crossref","first-page":"2200380","DOI":"10.1183\/13993003.00380-2022","article-title":"Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial","volume":"60","author":"Otsubo","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.bcp.2025.116928_b0925","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10637-021-01155-w","article-title":"Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer","volume":"40","author":"Omori","year":"2022","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.bcp.2025.116928_b0930","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/ph16030433","article-title":"Exploring the Application of Micellar Drug Delivery Systems in Cancer Nanomedicine","volume":"16","author":"Wang","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bcp.2025.116928_b0935","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00280-014-2498-5","article-title":"A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer","volume":"74","author":"Ahn","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bcp.2025.116928_b0940","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1097\/JTO.0000000000000692","article-title":"A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors","volume":"10","author":"Kim","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b0945","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.actbio.2020.12.009","article-title":"Clinical applications of nanomedicines in lung cancer treatment","volume":"121","author":"Norouzi","year":"2021","journal-title":"Acta Biomater"},{"key":"10.1016\/j.bcp.2025.116928_b0950","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2174\/1871520620666200719001038","article-title":"Recent Development of Copolymeric Nano-Drug Delivery System for Paclitaxel","volume":"20","author":"Chen","year":"2020","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.bcp.2025.116928_b0955","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijpharm.2017.05.016","article-title":"Paclitaxel: What has been done and the challenges remain ahead","volume":"526","author":"Bernabeu","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/j.bcp.2025.116928_b0960","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.biopha.2008.10.001","article-title":"A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors","volume":"63","author":"Zhang","year":"2009","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bcp.2025.116928_b0965","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cac2.12225","volume":"42","author":"Zhang","year":"2022","journal-title":"Cancer Commun (lond)"},{"key":"10.1016\/j.bcp.2025.116928_b0970","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1745-6215-14-45","article-title":"Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial)","volume":"14","author":"Hu","year":"2013","journal-title":"Trials"},{"key":"10.1016\/j.bcp.2025.116928_b0975","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/annonc\/mdm374","article-title":"Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer","volume":"18","author":"Kim","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b0980","doi-asserted-by":"crossref","unstructured":"Von Hoff, D.D.; Mita, M.M.; Ramanathan, R.K.; Weiss, G.J.; Mita, A.C.; LoRusso, P.M.; Burris, H.A., 3rd; Hart, L.L.; Low, S.C.; Parsons, D.M.; et al. Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. Clin Cancer Res 2016, 22, 3157-3163, doi:10.1158\/1078-0432.CCR-15-2548.","DOI":"10.1158\/1078-0432.CCR-15-2548"},{"key":"10.1016\/j.bcp.2025.116928_b0985","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1158\/1078-0432.CCR-0842-03","article-title":"Comparative pharmacokinetics of weekly and every-three-weeks docetaxel","volume":"10","author":"Baker","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2025.116928_b0990","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.3390\/ijms19071979","article-title":"Gold Nanoparticles in Diagnostics and Therapeutics for Human Cancer","volume":"19","author":"Singh","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bcp.2025.116928_b0995","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/863951","article-title":"Nanoparticle-based drug delivery for therapy of lung cancer: progress and challenges","volume":"2013","author":"Babu","year":"2013","journal-title":"J Nanomater"},{"key":"10.1016\/j.bcp.2025.116928_b1000","article-title":"Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans","volume":"7","author":"Lu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.116928_b1005","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/sj.leu.2404296","article-title":"Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication","volume":"20","author":"Ratajczak","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2025.116928_b1010","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCRESAHA.110.226456","article-title":"Microparticles: protagonists of a novel communication network for intercellular information exchange","volume":"107","author":"Mause","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.bcp.2025.116928_b1015","doi-asserted-by":"crossref","first-page":"1002938","DOI":"10.3389\/fimmu.2022.1002938","volume":"13","author":"Dong","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.bcp.2025.116928_b1020","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1101\/gad.192351.112","article-title":"Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers","volume":"26","author":"D'Souza-Schorey","year":"2012","journal-title":"Genes Dev"},{"key":"10.1016\/j.bcp.2025.116928_b1025","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/ncomms2282","article-title":"Delivery of chemotherapeutic drugs in tumour cell-derived microparticles","volume":"3","author":"Tang","year":"2012","journal-title":"Nat Commun"},{"key":"10.1016\/j.bcp.2025.116928_b1030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.biomaterials.2016.02.025","article-title":"Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy","volume":"89","author":"Ran","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.bcp.2025.116928_b1035","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1158\/2326-6066.CIR-14-0177","article-title":"Cell-free tumor microparticle vaccines stimulate dendritic cells via cGAS\/STING signaling","volume":"3","author":"Zhang","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.bcp.2025.116928_b1040","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1158\/2326-6066.CIR-17-0716","article-title":"Mechanisms by Which Dendritic Cells Present Tumor Microparticle Antigens to CD8(+) T Cells","volume":"6","author":"Ma","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.bcp.2025.116928_b1045","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/cr.2016.53","article-title":"Reversing drug resistance of soft tumor-repopulating cells by tumor cell-derived chemotherapeutic microparticles","volume":"26","author":"Ma","year":"2016","journal-title":"Cell Res"},{"key":"10.1016\/j.bcp.2025.116928_b1050","doi-asserted-by":"crossref","first-page":"eaat5690","DOI":"10.1126\/scitranslmed.aat5690","article-title":"Autologous tumor cell-derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion","volume":"11","author":"Guo","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bcp.2025.116928_b1055","doi-asserted-by":"crossref","unstructured":"Patra, J.K.; Das, G.; Fraceto, L.F.; Campos, E.V.R.; Rodriguez-Torres, M.d.P.; Acosta-Torres, L.S.; Diaz-Torres, L.A.; Grillo, R.; Swamy, M.K.; Sharma, S.; et al. Nano based drug delivery systems: recent developments and future prospects. Journal of Nanobiotechnology 2018, 16, 71, doi:10.1186\/s12951-018-0392-8.","DOI":"10.1186\/s12951-018-0392-8"},{"key":"10.1016\/j.bcp.2025.116928_b1060","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.addr.2003.12.002","article-title":"Solid lipid nanoparticles for parenteral drug delivery","volume":"56","author":"Wissing","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bcp.2025.116928_b1065","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers (basel)"},{"key":"10.1016\/j.bcp.2025.116928_b1070","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3390\/polym16172536","article-title":"Biodegradable Polymeric Nanoparticle-Based Drug Delivery Systems: Comprehensive Overview, Perspectives and Challenges","volume":"16","author":"Geszke-Moritz","year":"2024","journal-title":"Polymers"},{"key":"10.1016\/j.bcp.2025.116928_b1075","doi-asserted-by":"crossref","first-page":"10748","DOI":"10.1039\/D1NR02065J","article-title":"Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery","volume":"13","author":"Shi","year":"2021","journal-title":"Nanoscale"},{"key":"10.1016\/j.bcp.2025.116928_b1080","doi-asserted-by":"crossref","unstructured":"Munir, M.U. Nanomedicine Penetration to Tumor: Challenges, and Advanced Strategies to Tackle This Issue. Cancers (Basel) 2022, 14, doi:10.3390\/cancers14122904.","DOI":"10.3390\/cancers14122904"},{"key":"10.1016\/j.bcp.2025.116928_b1085","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1021\/acs.bioconjchem.9b00448","article-title":"Nanoparticle Interactions with the Tumor Microenvironment","volume":"30","author":"Huai","year":"2019","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.bcp.2025.116928_b1090","article-title":"Tumor extracellular matrix modulating strategies for enhanced antitumor therapy of nanomedicines","volume":"16","author":"Li","year":"2022","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.bcp.2025.116928_b1095","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijbiomac.2018.04.076","article-title":"Bromelain-immobilized and lactobionic acid-modified chitosan nanoparticles for enhanced drug penetration in tumor tissues","volume":"115","author":"Wang","year":"2018","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.bcp.2025.116928_b1100","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3390\/ph17101389","article-title":"Targeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications","volume":"17","author":"Debnath","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bcp.2025.116928_b1105","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.7150\/thno.104190","article-title":"Hypoxia-responsive nanoparticles for fluorescence diagnosis and therapy of cancer","volume":"15","author":"Zhang","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2025.116928_b1110","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2025.116928_b1115","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2025.116928_b1120","doi-asserted-by":"crossref","first-page":"1039378","DOI":"10.3389\/fonc.2022.1039378","article-title":"Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy","volume":"12","author":"Xiao","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.bcp.2025.116928_b1125","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.bcp.2025.116928_b1130","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317708547","article-title":"Conjugation of gold nanoparticles and recombinant human endostatin modulates vascular normalization via interruption of anterior gradient 2-mediated angiogenesis","volume":"39","author":"Pan","year":"2017","journal-title":"Tumour Biol"},{"key":"10.1016\/j.bcp.2025.116928_b1135","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jconrel.2014.03.057","article-title":"Evidence and fallacy","volume":"190","author":"Nichols","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.bcp.2025.116928_b1140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","article-title":"To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?","volume":"244","author":"Danhier","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.bcp.2025.116928_b1145","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijpharm.2007.06.028","article-title":"Human serum albumin (HSA) nanoparticles: Reproducibility of preparation process and kinetics of enzymatic degradation","volume":"347","author":"Langer","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bcp.2025.116928_b1150","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","article-title":"Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications","volume":"200","author":"Wicki","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2025.116928_b1155","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jconrel.2022.05.027","article-title":"Exosomes: Large-scale production, isolation, drug loading efficiency, and biodistribution and uptake","volume":"347","author":"Kimiz-Gebologlu","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.bcp.2025.116928_b1160","doi-asserted-by":"crossref","DOI":"10.3390\/cells8040307","article-title":"Review of the Isolation, Characterization, Biological Function, and Multifarious Therapeutic Approaches of Exosomes","volume":"8","author":"Gurunathan","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2025.116928_b1165","doi-asserted-by":"crossref","first-page":"6466","DOI":"10.3390\/ijms21186466","article-title":"A Review of Exosomal Isolation Methods: Is Size Exclusion Chromatography the Best Option?","volume":"21","author":"Sidhom","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bcp.2025.116928_b1170","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.addr.2021.03.017","article-title":"Exploring interactions between extracellular vesicles and cells for innovative drug delivery system design","volume":"173","author":"Kooijmans","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bcp.2025.116928_b1175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2020.183490","article-title":"Exosomes isolated from two different cell lines using three different isolation techniques show variation in physical and molecular characteristics","volume":"1863","author":"Dash","year":"2021","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"10.1016\/j.bcp.2025.116928_b1180","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1039\/c2lc41006k","article-title":"Microfluidic filtration system to isolate extracellular vesicles from blood","volume":"12","author":"Davies","year":"2012","journal-title":"Lab Chip"},{"key":"10.1016\/j.bcp.2025.116928_b1185","doi-asserted-by":"crossref","first-page":"789","DOI":"10.7150\/thno.18133","article-title":"Progress in Exosome Isolation Techniques","volume":"7","author":"Li","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2025.116928_b1190","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13287-017-0510-9","article-title":"Comparison of exosomes secreted by induced pluripotent stem cell-derived mesenchymal stem cells and synovial membrane-derived mesenchymal stem cells for the treatment of osteoarthritis","volume":"8","author":"Zhu","year":"2017","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.bcp.2025.116928_b1195","doi-asserted-by":"crossref","first-page":"e1519","DOI":"10.1002\/wnan.1519","article-title":"Strategies to improve tumor penetration of nanomedicines through nanoparticle design","volume":"11","author":"Zhang","year":"2019","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1016\/j.bcp.2025.116928_b1200","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1002\/anie.200900063","article-title":"A supramolecular approach for preparation of size-controlled nanoparticles","volume":"48","author":"Wang","year":"2009","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.bcp.2025.116928_b1205","doi-asserted-by":"crossref","first-page":"12721","DOI":"10.1002\/anie.201205271","article-title":"Aptamer-functionalized, ultra-small, monodisperse silica nanoconjugates for targeted dual-modal imaging of lymph nodes with metastatic tumors","volume":"51","author":"Tang","year":"2012","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.bcp.2025.116928_b1210","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/j.biomaterials.2004.07.023","article-title":"Development of functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells","volume":"26","author":"Petri-Fink","year":"2005","journal-title":"Biomaterials"},{"key":"10.1016\/j.bcp.2025.116928_b1215","first-page":"1275","article-title":"Evaluation of uptake and transport of cationic and anionic ultrasmall iron oxide nanoparticles by human colon cells","volume":"7","author":"Kenzaoui","year":"2012","journal-title":"Int J Nanomedicine"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522500190X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522500190X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:57:31Z","timestamp":1785499051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522500190X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":243,"alternative-id":["S000629522500190X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116928","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoformulations: Reforming treatment for non-small cell lung cancer metastasis","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116928"}}